Photo via New York Post

Popular blood pressure drug recalled over dissolution issues

Read the original at New York Post ↗
Cite

Sacks, R. (2026, September 29). Popular blood pressure drug recalled over dissolution issues. New York Post. https://nypost.com/2026/09/29/health/why-is-the-blood-pressure-drug-chlorthalidone-being-recalled/

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

New York Post · collected 2026-09-29 · by Rachel Sacks

Quick Summary

Inventia Healthcare Limited has recalled 13,567 bottles of Chlorthalidone Tablets due to failing dissolution testing, affecting their ability to lower blood pressure effectively. This recall is the second this year for Inventia’s chlorthalidone product and falls under the FDA's Class II category, indicating a remote probability of serious adverse health consequences if the medication does not work properly. The article emphasizes the importance of consulting healthcare providers before discontinuing use of recalled medications to avoid potential risks associated with sudden changes in blood pressure management.
Written by AI on 2026-09-29, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

Inventia Healthcare Limited, based in India, has voluntarily recalled 13,567 bottles of Chlorthalidone Tablets, USP, 25 mg (NDC: 64980-599-01, Batch No. RISA24002, expiration date April 2027) after the tablets failed dissolution testing. This is the second recall of chlorthalidone by the company this year; earlier in June, 11,460 bottles were recalled due to similar issues. The FDA categorized both recalls as Class II, indicating that their use may cause temporary or medically reversible adverse health consequences but does not pose a high risk of serious harm. Chlorthalidone is a diuretic used for treating hypertension by increasing urine production and reducing excess salt in the body.

Written for “Blood Pressure Drug Recall” on 2026-11-02, grounded in this article and the 0 other(s) covering the same event.

Story

📰 Blood Pressure Drug Recall
Health · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
18
sentences that state something as happening or true
Uncertain
28%
5 of 18 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
66/100
New York Post's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-09-29 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

New York Post · 15921 article(s) · 35 correction(s) detected
Running correction rate · 35 correction(s)

Who wrote this

Rachel Sacks
37 article(s) here · 1 carrying a prediction
🔮 The good news is that an innovative treatment could not only replace the dental drill, but also spare those who brush off scheduling their next checkup.
🔮 The results of the phase 3 trial could offer hope for a disease that kills more than 97,000 people around the world each year.
🔮 A widespread problem, hair loss affects roughly 50 million men and 30 million women, and while there’s no special potion to reverse genetic or age-related decline, some products may slow down loss and promote regrowth.
🔮 Depressive symptoms may look similar, but there are various underlying causes.
🔮 The race is intended to give all kids the confidence boost that comes with crossing a finish line and hearing crowds cheering for them, with Collins noting that for some “it could be their first ever fitness event.”
🔮 And while a little meal before bedtime may curb your hunger in the short term, eating at the wrong time could increase the risk of a severe disease that causes permanent damage.
🔮 Massages may provide short-term relief for pain in the neck, shoulders, lower back and knees, as well as a part of supportive care for cancer patients.
2026-10-18 · assertive framing · You can now get a robot massage designed by Tom Brady
🔮 “The FDA should do whatever it possibly could do to get their hands on the actual drug that was injected by both of these patients,” associate professor at Harvard Medical School Pieter Cohen told CBS News.
🔮 Now, a revolutionary treatment may provide relief for the joint inflammation, pain, stiffness and reduced mobility that often come with arthritis or other knee injuries.
🔮 A silent yet deadly epidemic is sweeping the nation, with the number of Americans living with heart failure expected to nearly double from 6.7 million in 2024 to 11.4 million by 2050.
Also by Rachel Sacks
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 37 articles by Rachel Sacks →

Topics

Chlorthalidone Tablets FDA India Inventia Healthcare Inventia Healthcare Limited

Subjects

FDA ORG · 3× American College of Cardiology ORG · 1× American Heart Association ORG · 1× India GPE · 1× Inventia Healthcare ORG · 1× Inventia Healthcare Limited ORG · 1×

Narrative

Inventia Healthcare Limited is voluntarily recalling 13,567 bottles of Chlorthalidone Tablets, USP, 25 mg (NDC: 64980-599-01, Batch No. RISA24002, expiration date April 2027) after they failed dissolution testing, which measures how the drug dissolves in the body.
framing: mixed · carried by 1 article(s) · first seen 2026-09-29
🔮 The FDA identified both recalls as Class II, which is “a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”
2026-09-29 · New York Post
Popular blood pressure drug recalled over dissolution issues · mixed framing

Claims (18 extracted, 5 hedged)

Thousands of bottles of a popular blood pressure medication are being recalled over concerns about effectiveness. asserted
Thousands → recall → effectiveness
Inventia Healthcare Limited is voluntarily recalling 13,567 bottles of Chlorthalidone Tablets, USP, 25 mg (NDC: 64980-599-01, Batch No. RISA24002, expiration date April 2027) after they failed dissolution testing, which measures how the drug dissolves in the body. asserted
drug → recall → body
This is the second time the company, based in India, has recalled chlorthalidone this year. asserted
company → base → chlorthalidone
A voluntary recall happens when manufacturers or distributors “carry out their responsibility” to protect the public health of those who use their product. asserted
who → happen → product
Inventia Healthcare first recalled 11,460 bottles of the blood pressure medication in both 100-tablet and 1,000-tablet sizes on June 5. asserted
Healthcare → recall → June
The FDA identified both recalls as Class II, which is “a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.” uncertain
probability → identify → consequences
Chlorthalidone is a diuretic, or water pill, that causes the kidneys to get rid of unnecessary salt and water by increasing urine, which helps to lower blood pressure. asserted
which → cause → pressure
When a medication fails dissolution testing, the active ingredient is not only not properly absorbed, but may also not work effectively. uncertain
ingredient → fail → testing
Reduced efficacy of a drug to manage high blood pressure could increase the risk of stroke, heart attack, kidney damage and other complications over time. uncertain
efficacy → reduce → time
Those who are taking the recalled medication should contact their healthcare provider before stopping taking the medication. asserted
who → take → medication
For class II and III recalls, the FDA states that “consumers can generally continue taking the medicine unless the recalling company provides other instructions.” asserted
company → state → instructions
Abruptly stopping medication could be dangerous, resulting in blood pressure rising too quickly, increased risk of stroke or heart attack, kidney damage and withdrawal symptoms. uncertain
pressure → stop → stroke
To check whether your medicine is affected, compare the lot numbers. asserted
medicine → check → numbers
The batch codes for the recalled tablets are: RISA24001 RISB24002 RISA24002 The recall numbers, as posted by the FDA, are D-0852-2026 and D-0610-2026. asserted
numbers → recall → FDA
More than half of US adults have high blood pressure — around 119 million — with 70% or more experiencing hypertension by age 70. asserted
% → have → age
Defined as a consistent reading of 130/80 milligrams of mercury (mm Hg) or higher, many people take medication to manage their condition. asserted
people → define → condition
The most recent guidelines from the American Heart Association and American College of Cardiology recommend taking medications sooner rather than later, depending on someone’s diagnosis and risk. asserted
guidelines → recommend → diagnosis
While diuretics are a commonly used medication, many people need at least two options, which may also include angiotensin-receptor blockers (ARBs), ACE inhibitors and calcium-channel blockers. uncertain
which → use → blockers
💬Give feedback
🕘History 🎫Support